VC investor Andera Partners opens office in the Innovation and Start-up Center Biotechnology (IZB)
Andera Partners’ life sciences team invests internationally in biotech and medtech companies
Olivier Litzka, Partner, Andera Partners
Martinsried near Munich, October 17, 2022 – The Biotechnology Innovation and Start-up Center (IZB), one of the leading biotechnology centers in Europe with more than 50 resident biotech start-ups, announced today that European investor Andera Partners has moved into the IZB in Martinsried near Munich on October 1, 2022. The 15-member life sciences team of Andera Partners, based in Paris, has extensive experience in the life sciences industry as well as in private equity and venture capital. Active since 2000, the team has raised more than €1.1 billion through its BioDiscovery family of funds and is currently investing from its new BioDiscovery 6 fund. Since their inception, the BioDiscovery funds have invested in more than 75 European and U.S. biotech and medtech companies.
“We are pleased to welcome Andera Partners to IZB. The presence of this important European life science investor at our campus underpins our position as a leading biotechnology location in Germany and in Europe. I am sure that this will create interesting synergies from which both the start-ups located here and Andera can benefit,” added Dr. Peter Hanns Zobel, Managing Director IZB.
“We invest in companies that develop breakthrough therapeutic products and medical technologies from the preclinical phase to commercialization,” said Olivier Litzka, now Munich-based partner at Andera. “In doing so, our company focuses on developing innovative medical solutions based on sound scientific hypotheses, supported by preclinical or clinical data and protected by strong intellectual property. In its investments, Andera takes an active role in supporting talented entrepreneurs who consistently drive their innovations forward. I am very much looking forward to a lively exchange in the environment of IZB, Martinsried and Munich.
About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
The Fördergesellschaft IZB mbH, founded in 1995, operates the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan and has developed into a leading biotechnology center. More than 50 biotech companies with over 700 employees are currently based on 26,000 m2. Here, work is being done on developing drugs for the most serious diseases, such as cancer, Alzheimer’s and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt chemistry college, the two kindergartens Bio Kids and Bio Kids2 as well as the two restaurants SEVEN AND MORE and THE BOWL Food Lounge are also location factors that are highly valued by the founders of the company. Successful companies that emerged from the IZB include Corimmun (today Janssen-Cilag), Coriolis, Exosome Diagnostics (bought by Bio-Techn), ibidi, Immunic Therapeutics, Medigene, Micromet (today Amgen), MorphoSys, Octopharma or Rigontec (now MSD). More information at www.izb-online.de
Press contact and image material requests:
Susanne Simon, Head of Press and Public Relations
Innovation and Start-up Center for Biotechnology (IZB)
Am Klopferspitz 19
Tel.: +49 (0)89/55 279 48-17